|Titre :||Buprenorphine implants for treatment of opioid dependence. A randomized controlled trial (2010)|
|Auteurs :||W. LING ; P. CASADONTE ; G. BIGELOW ; K. M. KAMPMAN ; A. A. PATKAR ; G. L. BAILEY ; R. N. ROSENTHAL ; K. L. BEEBE|
|Type de document :||Article : Périodique|
|Dans :||Journal of the American Medical Association (Vol.304, n°14, October 13, 2010)|
|Article en page(s) :||1576-1583|
|Note générale :||Editorial: "Advances in the treatment of opioid dependence: continued progress and ongoing challenges", O'Connor P.G., p.1612-1614. Letters to the editor & author's reply: "Buprenorphine implants and opioid dependence", D.A. Rastegar, JAMA 2011;305(3):253-5.|
|Discipline :||TRA (Traitement et prise en charge / Treatment and care)|
Thésaurus TOXIBASEETUDE RANDOMISEE ; BUPRENORPHINE ; TRAITEMENT DE MAINTENANCE ; VOIE D'ADMINISTRATION ; EFFICACITE ; OPIOIDES
Context: Limitations of existing pharmacological treatments for opioid dependence include low adherence, medication diversion, and emergence of withdrawal symptoms.
Objective: To determine the efficacy of buprenorphine implants that provide a low, steady level of buprenorphine over 6 months for the treatment of opioid dependence.
Design, Setting, and Participants: A randomized, placebo-controlled, 6-month trial conducted at 18 sites in the United States between April 2007 and June 2008. One hundred sixty-three adults, aged 18 to 65 years, diagnosed with opioid dependence. One hundred eight were randomized to receive buprenorphine implants and 55 to receive placebo implants.
Intervention: After induction with sublingual buprenorphine-naloxone tablets, patients received either 4 buprenorphine implants (80 mg per implant) or 4 placebo implants. A fifth implant was available if a threshold for rescue use of sublingual buprenorphine-naloxone treatment was exceeded. Standardized individual drug counseling was provided to all patients.
Main Outcome Measure: The percentage of urine samples negative for illicit opioids for weeks 1 through 16 and for weeks 17 through 24.
Results: The buprenorphine implant group had significantly more urine samples negative for illicit opioids during weeks 1 through 16 (P = .04). Patients with buprenorphine implants had a mean percentage of urine samples that tested negative for illicit opioids across weeks 1 through 16 of 40.4% (95% confidence interval [CI], 34.2%-46.7%) and a median of 40.7%; whereas those in the placebo group had a mean of 28.3% (95% CI, 20.3%-36.3%) and a median of 20.8%. A total of 71 of 108 patients (65.7%) who received buprenorphine implants completed the study vs 17 of 55 (30.9%) who received placebo implants (P Conclusion: Among persons with opioid dependence, the use of buprenorphine implants compared with placebo resulted in less opioid use over 16 weeks as assessed by urine samples. [Author's abstract]
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States / Etats-Unis|